News
AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma.
Q1 2025 Earnings Call Transcript April 29, 2025 AstraZeneca PLC beats earnings expectations. Reported EPS is $1.3, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback